Objective: Therapeutic drug monitoring of clozapine may be useful for the clinical management of schizophrenic patients treated with this atypical antipsychotic drug. The aim of our study was the evaluation of three models for the prediction of steady-state trough clozapine concentration.

Patients And Methods: The trough serum concentrations of clozapine and norclozapine were determined by high-performance liquid chromatography in 296 samples from a group of 21 schizophrenic patients selected for their good therapeutic compliance. Also, the predicted clozapine concentrations were estimated by applying the models of Oyewumi et al. (Ther Drug Monit 1995; 17: 137), Perry et al. (Biol Psychiatry 1998; 44: 733) and Rostami-Hodjegan et al. (J Clin Psychopharmacol 2004; 24: 70).

Results: The efficiency for the accurate estimation of clozapine concentrations as subtherapeutic (<240 ng/mL), therapeutic (240-750 ng/mL) or supratherapeutic (>750 ng/mL), using the models of Oyewumi et al., Perry et al., and Rostami-Hodjegan et al., was 82%, 71% and 77% respectively.

Conclusions: The predictive model of Oyewumi et al., which shows an easy calculation way and the greater diagnostic efficiency, may be of clinical value for the prediction of clozapine concentration or the dose required to achieve a specified concentration.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinbiochem.2008.01.020DOI Listing

Publication Analysis

Top Keywords

clozapine concentrations
12
evaluation three
8
models prediction
8
prediction steady-state
8
steady-state trough
8
trough clozapine
8
schizophrenic patients
8
models oyewumi
8
clozapine
7
three dosing
4

Similar Publications

Need to consider exact trough time: Comment on "Daily dosing frequency as a determinant of clozapine concentration-to-dose ratio: Data from a therapeutic drug monitoring service (2019-2022)".

Clin Chim Acta

December 2024

Department of Psychiatry, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan; Department of Psychiatry, Kodama Hospital, Ishinomaki, Miyagi, Japan. Electronic address:

View Article and Find Full Text PDF

Purpose/background: Clozapine is the recommended drug for treatment-resistant schizophrenia. Drug response could be affected by numerous factors such as age, sex, body mass index, co-medication, consumption of xanthine-containing beverages, smoking, and genetic variants of the enzymes involved in clozapine metabolism (CYP1A2, CYP3A4, and, to a lesser extent, CYP2C19 and CYP2D6). This study evaluated genetic and nongenetic variables that may affect clozapine plasma concentrations in Uruguayan patients with schizophrenia.

View Article and Find Full Text PDF

The involvement of drug-metabolizing enzymes and transporters in plasma clozapine (CLZ) dynamics has not been well examined in Japanese patients with treatment-resistant schizophrenia (TRS). Therefore, this clinical study investigated the relationship between single nucleotide polymorphisms (SNPs) of various pharmacokinetic factors (drug-metabolizing enzymes and transporters) and dynamic changes in CLZ. Additionally, we aimed to determine whether CLZ acts as a substrate for pharmacokinetic factors using in vitro assays and molecular docking calculations.

View Article and Find Full Text PDF

Clozapine is a functional antagonist at cardiac human H-histamine receptors.

Naunyn Schmiedebergs Arch Pharmacol

December 2024

Institute for Pharmacology and Toxicology, Medical Faculty, Martin-Luther-University Halle-Wittenberg, Magdeburger Straße 4, Halle (Saale), D-06097, Germany.

Clozapine is an atypical antipsychotic (neuroleptic) drug. Clozapine binds to H-histamine receptors in vitro. We wanted to test the hypothesis that clozapine might be a functional antagonist at human cardiac H-histamine receptors.

View Article and Find Full Text PDF
Article Synopsis
  • Strong evidence supports therapeutic drug monitoring (TDM) for olanzapine and clozapine, but TDM for olanzapine is often underused despite its effectiveness.
  • A case study of a 32-year-old male with schizoaffective disorder demonstrated that while olanzapine dosing revealed high levels indicating poor metabolism, pharmacogenetic tests did not provide useful information about his drug metabolism.
  • The conclusion emphasizes the importance of TDM over pharmacogenomic testing for managing medications like olanzapine and clozapine, especially in patients suspected of having altered CYP1A2 metabolism.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!